Selected cancer vaccines in Phase III testing, sorted by milestone date. (A) Trial completion indicates final data collection date for primary endpoint; Source: BCIQ: BioCentury Online Intelligence; company press releases; www.clinicaltrials.gov

Company

Product

Description

Lead indication

Lead status (milestone)

Accentia Biopharmaceuticals Inc.

BiovaxID

Autologous vaccine containing tumor-specific idiotype proteins from individual patient's lymphoma cells and conjugated to keyhole limpet hemocyanin (KLH)

Indolent follicular B cell non-Hodgkin's lymphoma (NHL)

Ph III (submit reg apps in Canada and Europe by YE2012)

Kael-Gemvax Co. Ltd.

GV1001

Vaccine targeting human telomerase reverse transcriptase (hTERT)

Metastatic and/or advanced pancreatic cancer; advanced non-small cell lung cancer (NSCLC)

Ph III (pancreas data 2H12); Ph III (NSCLC compl 2016) (A)